# Disentangling the relationship between cancer mortality and COVID-19 in the US

- 3 Authors: Chelsea L. Hansen<sup>1,2,3</sup>, Cécile Viboud<sup>1</sup>, Lone Simonsen<sup>1,2</sup>
- <sup>4</sup> <sup>1</sup>Division of International Epidemiology and Population Studies, Fogarty
- 5 International Center, National Institutes of Health, Bethesda, MD, USA. 20892
- <sup>6</sup> <sup>2</sup>PandemiX Center, Dept of Science & Environment, Roskilde University,
- 7 Denmark
- <sup>8</sup> <sup>3</sup>Brotman Baty Institute, University of Washington, Seattle, WA
- 10 Word count: 6972 (excluding headings and appendix)

- ...

#### 24

#### 25 Abstract: 447 words

26 Several countries have reported that deaths with a primary code of cancer did not rise during 27 COVID-19 pandemic waves compared to baseline pre-pandemic levels. This is in apparent 28 conflict with findings from cohort studies where cancer has been identified as a risk factor for 29 COVID-19 mortality. Here we further elucidate the relationship between cancer mortality and 30 COVID-19 on a population level in the US by testing the impact of death certificate coding 31 changes during the pandemic and leveraging heterogeneity in pandemic intensity across US 32 states. We computed excess mortality from weekly deaths during 2014-2020 nationally and for 33 three states with distinct COVID-19 wave timing (NY, TX, and CA). We compared pandemic-34 related mortality patterns from underlying and multiple cause (MC) death data for six types of cancer and compared to that seen for chronic conditions such as diabetes and Alzheimer's. Any 35 36 death certificate coding changes should be eliminated by study of MC data.

37 Nationally in 2020, we found only modest excess MC cancer mortality (~13,600 deaths), 38 representing a 3% elevation over baseline level. Mortality elevation was measurably higher for 39 less deadly cancers (breast, colorectal, and hematologic, 2-7%) than cancers with a poor 5-year 40 survival (lung and pancreatic, 0-1%). In comparison, there was substantial elevation in MC 41 deaths from diabetes (37%) and Alzheimer's (19%). Homing in on the intense spring 2020 42 COVID-19 wave in NY, mortality elevation was 1-16% for different types of cancer and 128% 43 and 49% for diabetes and Alzheimer's, respectively. To investigate the peculiar absence of 44 excess mortality on deadly cancers, we implemented a demographic model and simulated the 45 expected covid-related mortality using COVID-19 attack rates, life expectancy, population size 46 and mean age for each chronic condition. This model indicates that these factors largely explain 47 the considerable differences in observed excess mortality between these chronic conditions 48 during the COVID-19 pandemic, even if cancer had increased the relative risk of mortality by a

49 factor of 2 or 5.

50 In conclusion, we found limited elevation in cancer mortality during COVID-19 waves, even after

51 considering MC mortality, and this was especially pronounced for the deadliest cancers. Our

52 demographic model predicted low expected excess mortality in populations living with certain

types of cancer, even if cancer is a risk factor for COVID-19 fatality, due to competing mortality

risk. We also find a moderate increase in excess mortality from hematological cancers, aligned

55 with other types of observational studies. While our study concentrates on the immediate

56 consequences of the COVID-19 pandemic on cancer mortality in 2020, further research should

57 consider excess mortality in the complete pandemic period. Also, a study of the delayed impact

58 of the pandemic on cancer mortality due to delayed diagnosis and treatment during the

59 pandemic period is warranted.

#### 60 Introduction

61 The dominant risk factors for COVID-19 mortality have consistently been shown to be advanced 62 age, male gender and certain chronic diseases such as diabetes, obesity and heart disease 63 (Chavez-MacGregor et al., 2022; Rüthrich et al., 2021; Williamson et al., 2020), Cancer has also 64 been identified as a high-risk condition based on case-control and cohort studies, although these studies have provided conflicting results. In a large cohort study of ~500,000 COVID-19 65 66 inpatients, only cancer patients under recent treatment were at increased risk of COVID-19 67 related deaths (OR=1.7) relative to non-cancer patients (Chavez-MacGregor et al., 2022). Conversely, a smaller European study of 3,000 COVID-19 inpatients found that cancer was not 68 69 a risk factor (Rüthrich et al., 2021), as did an international, multicenter study of 4,000 confirmed 70 COVID-19 inpatients (Raad et al., 2023). More recently a meta-analysis of 35 studies from 71 Europe, North America, and Asia found a 2-fold increased risk of COVID-19 mortality among 72 cancer patients (Di Felice et al., 2022). Similarly, a large analysis from the UK found that the risk 73 of COVID-19 mortality for cancer patients had declined over the course of the pandemic but 74 remained 2.5 times higher than for non-cancer patients into 2022 (Starkey et al., 2023). Taken 75 together, such observational studies provide a mixed picture of cancer as a COVID-19 mortality 76 risk factor, with several studies reporting that controlling for important factors such as age is a 77 challenge. Furthermore, cancer is often considered as a single disease category despite the 78 diversity of conditions and patients represented.

79 Further evidence for the relationship between cancer and COVID-19 comes from population-80 level analysis of vital statistics. A recent US study showed no elevation in underlying cancer 81 deaths concomitant with COVID-19 waves, in stark contrast to the sharp rise in mortality from 82 other chronic diseases (W.-E. Lee et al., 2023). In several other countries, including Sweden, 83 Italy, Latvia, Brazil, England and Wales, underlying cancer mortality was found to be stable or decreasing during the first year of the pandemic (Alicandro et al., 2023; Fernandes et al., 2021; 84 85 Gobina et al., 2022; Grande et al., 2022; Kontopantelis et al., 2022; Lundberg et al., 2023). Further, an excess mortality study of 240,000 cancer patients in Belgium found a 33% rise in 86 87 mortality in April 2020, but concluded that this was no different from the rise observed in the 88 general population (Silversmit et al., 2021). The apparent lack of association between cancer

- 89 mortality and COVID-19 on a population level raises the question of the true relationship
- 90 between cancer and COVID-19.

91 The relationship between these two diseases could occur via multiple biological mechanisms. 92 First, immunosuppression in cancer patients could increase susceptibility to SARS-CoV-2 93 infection and/or risk of severe clinical outcome upon infection. Conversely, immunosuppression 94 could act as a protective factor in the face of a severe respiratory infection that kills by over-95 stimulating the immune system - the immune incompetence rescue hypothesis (Reichert 2004). 96 This hypothesis was put forward to explain the observed absence in excess cancer mortality 97 during the 1968 influenza pandemic, a departure from elevated mortality seen for other high-risk 98 conditions such as heart disease and diabetes (Reichert 2004). A further mechanism that could 99 affect the observed relationship between cancer deaths and COVID-19 is changing guidelines 100 for establishing the primary cause of death. Coding guidelines evolved throughout the pandemic 101 as testing for SARS-CoV-2 infection became more widespread, which presumably affected vital102 statistics studies.

103 To further elucidate the relationship between cancer mortality and COVID-19 on a population 104 level, we analyzed US vital statistics in detail to understand the potential role of death certificate 105 coding changes during the pandemic and explored putative differences in mortality patterns between different types of cancer. We considered death certificates listing cancer as the 106 107 underlying cause of death (UC) or anywhere on the death certificate (multiple-cause (MC)). 108 Assuming there is a high propensity to attribute a primary code of COVID-19 during the 109 pandemic in any patient with COVID-19, deaths among individuals with both cancer and 110 COVID-19 near the time of death would be coded as UC COVID-19. However, cancer should 111 still be captured in the MC data, and thus, analysis of MC death data should control for any 112 changes in death certificate coding practices during the pandemic (Fedeli et al., 2024). The US 113 provides a particularly useful case study as the timing of COVID-19 waves varied considerably 114 between states, so that elevations in cancer deaths, should they exist, should also be 115 heterogeneous. For comparison, we also assessed population-level excess mortality patterns

- for other chronic conditions such as diabetes, ischemic heart disease (IHD), kidney disease,
- and Alzheimer's, for which the association with COVID-19 is less debated.

#### 118 Results

#### 119 Establishing patterns and timing of COVID-19 related deaths

120 We obtained individual ICD-10 coded death certificate data from the US for the period January 1, 2014, to December 31, 2020. We compiled time series by week and cause of death, for 121 122 underlying cause (UC) and for multiple-cause (MC) mortality. We considered 10 causes of 123 death, including diabetes, Alzheimer's disease, ischemic heart disease (IHD), kidney disease, 124 and 6 types of cancer (all-cause cancer, colorectal, breast, pancreatic, lung, and hematological; 125 see Table 1 and Appendix 1 - Table 1 for a list of disease codes). We chose these specific 126 cancers to illustrate conditions for which the 5- year survival rate is low (13% and 25%, 127 respectively, for pancreatic and lung cancers) and high (65% and 91%, respectively, for 128 colorectal and breast cancers) (National Cancer Institute, n.d.). Hematological cancer (67% 5-129 year survival rate) was included because it has been singled out as a risk factor in several 130 previous studies due to the immune suppression associated with both its malignancy and 131 treatment. (Chavez-MacGregor et al., 2022; X. Han et al., 2022; Rüthrich et al., 2021; 132 Williamson et al., 2020). To compare mortality patterns with the timing of COVID-19 pandemic 133 waves, we accessed national and state-level counts of reported COVID-19 cases from the 134 Centers for Disease Control and Prevention (CDC)(Centers for Disease Control and Prevention, 135 2022).

In national data, time series of COVID-19-coded death certificates (both UC and MC) tracked
with the temporal patterns of laboratory-confirmed COVID-19 cases (Figure 1), revealing three
distinct COVID-19 waves: a spring wave peaking on April 12, 2020, a smaller summer wave
peaking on July 26, 2020, and a large winter wave that had not yet peaked by the end of the

- 140 study in December 2020. This correspondence between COVID-19 case and death activity
- 141 represents a "signature" mortality pattern of COVID-19.

142 Analysis of state-level data reveals variable timing, intensity, and number of COVID-19 waves 143 across the US during 2020. To focus on periods with substantial COVID-19 activity and explore 144 the association with cancer, we identified three large US states with unique, well-defined waves 145 (Figure 1). New York (NY) state experienced a large, early wave in March-May 2020, based on 146 recorded COVID-19 cases and deaths and high seroprevalence of SARS-CoV-2 antibodies in 147 this period (over 20% (Stadlbauer et al., 2021)). Meanwhile, California (CA) experienced a large 148 COVID-19 wave at the end of the year and had little activity during the spring and summer. 149 Finally, Texas (TX) had two large waves; one during late summer, followed by one in winter

- 150 2020.
- 151 National patterns in excess mortality from cancer

152 Similar to other influenza and COVID-19 population-level mortality studies (Islam et al., 2021;

153 Karlinsky and Kobak, 2021; W.-E. Lee et al., 2023; Msemburi et al., 2023), we established a

- 154 weekly baseline model for expected mortality in the absence of pandemic activity by modeling
- time trends and seasonality in pre-pandemic data and letting the model run forward during the
- 156 pandemic (see Methods). Each cause of death (UC and MC) and geography (aggregated
- National, NY, TX, and CA) was modeled separately. We then computed excess mortality as the
   difference between observed deaths and the model-predicted baseline. We summed weekly
- estimates to calculate excess mortality for the full pandemic period and during each of the 3
- 160 waves (see Methods). In addition to these absolute effects of the pandemic on mortality, we
- 161 also calculated the relative effects by dividing excess mortality by baseline mortality. This
- 162 approach has been used in the past to standardize mortality effects in strata with very different
- 163 underlying risks (e.g., age groups, geographies, or causes of death, see Methods).
- 164 Nationally, we found a drop in UC cancer deaths during spring 2020 (Figure 2, panel a; Table
- 165 2), although the drop was not statistically significant. A similar non-significant decline was also
- seen for specific cancer types (Figure 2, panels d-f; Appendix 1 Figure 1, panels a,f-j). Further,
- 167 pre-pandemic mortality trends for each cancer type continued unabated during the first
- 168 pandemic year. We reasoned that this early drop in UC cancer deaths may be explained by
- 169 changes in coding practices, so we next turned to MC mortality to resolve this question.
- 170 Time series of MC cancer mortality showed a significant increase in all three waves (Figure 2,
- panel a; Appendix 1 Table 2). A similar pattern was seen in MC time series for colorectal
- 172 (Figure 2, panel h), breast (Appendix 1 Figure 1, panel i), and hematological cancer (Appendix
- 173 1 Figure 1, panel j). However, the total excess mortality was modest with 13,600 excess
- 174 cancer deaths in 2020, representing a statistically significant 3% elevation over baseline (Table
- 175 2). The largest relative increase in MC mortality was observed in hematological cancer at 7%
- 176 (statistically significant, 3,600 excess deaths). No excess in MC mortality was seen for the two
- deadliest cancers, pancreatic cancer (Figure 2, panel f) and lung cancer (Appendix 1 Figure 1,
- 178 panel g).

#### 179 <u>National patterns in deaths due to other chronic conditions</u>

180 We considered diabetes and Alzheimer's as "positive controls" as they are also considered 181 COVID-19 risk factors and can illustrate how positive associations between chronic conditions 182 and COVID-19 manifest in population level excess mortality studies. Diabetes provides a 183 particularly useful comparator for cancer as the mean age at death is similar (~72 years, Table 184 1) and because few individuals live in a nursing home (Appendix 1 - Supplemental Methods). 185 Mortality time series from UC and MC diabetes and Alzheimer's were highly correlated with 186 COVID-19 activity, with statistically significant mortality elevation synchronous with pandemic 187 waves (Figure 2 b-c; Appendix 1 - Figures 2-5). For diabetes, we measured an excess of 10,800 188 and 82,300 deaths (UC and MC, respectively), corresponding to statistically significant 189 elevations of 16% and 37% over baseline level mortality (Table 2). For Alzheimer's, we 190 estimated 8,500 and 21,700 excess deaths, corresponding to statistically significant elevations 191 of 9% and 19% elevation over baseline, respectively. Pandemic-related excess mortality was

also seen for IHD and kidney disease (see supplement for estimates, Appendix 1 - Table 2).

#### 193 <u>State-level patterns in excess mortality</u>

Similar to patterns seen in national level data, none of the state-level analyses revealed notable
increases in UC cancer mortality, while there was a modest, non-significant increase in MC
cancer mortality (Figures 3-5; Appendix 1 - Figures 6-8). The largest mortality increase was
seen in NY during the spring wave, with a 6% rise in MC cancer mortality above the model
baseline (Table 2; Appendix 1 - Table 3). The magnitude of the increase seen during the spring

199 wave varied by cancer type, with minimal increases seen in pancreatic and lung cancers (1%)

and higher increases in colorectal, hematological, and breast cancers (9%, 10%, and 16%,

201 respectively). For comparison, there was a statistically significant rise in Alzheimer's and

diabetes deaths during this wave of 49% and 128%.

203 In CA and TX, mortality fluctuations were less pronounced than in NY, coinciding with less 204 intense COVID-19 waves, and this was seen across all conditions. MC excess mortality 205 estimates remained within +/-4% of baseline levels for cancers, irrespective of the type of 206 cancer and pandemic wave, except for hematological cancers which saw an 11% rise in Texas 207 during the summer wave and an 8% rise in California during the winter wave. None of these 208 elevations were statistically significant. In comparison, there was statistically significant excess 209 mortality elevation for both Alzheimer's and diabetes deaths (range, 18-59% in the CA winter 210 wave, and 45-77% in the TX summer wave, Table 2, Appendix 1- Tables 4-5).

# 211 <u>Demographic mortality projections under the null hypothesis that cancer in and of itself is not a</u> 212 <u>risk factor for COVID-19 mortality</u>

213 Next, to get a sense of the expected mortality elevation, we ran simulations to gauge the level of

214 individual-level association (traditionally measured as relative risk, RR) between COVID-19 and

the studied chronic conditions that is consistent with the population-level excess mortality

216 patterns observed during the pandemic. Using cancer as an example, two main factors could

217 drive cancer mortality patterns during COVID-19, namely the size and age of the population

- 218 living with cancer (since age is such a pronounced risk factor for COVID-19), and the life 219 expectancy under cancer diagnosis. These factors would operate irrespective of the true
- 220 biological relationship between COVID-19 severity and cancer. The same logic applies to
- 221 mortality from other chronic conditions, such as diabetes or Alzheimer's.

222 To test the hypothesis that these population factors alone could explain differences in excess 223 mortality between chronic conditions, we designed a simple model of COVID-19 mortality for 224 individuals with chronic conditions (see methods for details). The model projected excess 225 mortality during the pandemic under the null hypothesis that the chronic condition was not in 226 and of itself a risk factor for COVID-19 mortality, with only the demography of the population 227 living with the disease (namely, the age and size of the at-risk populations and baseline risk of 228 death from each condition) affecting excess mortality. In the demographic model, we first 229 estimated the number of expected SARS-CoV-2 infections among persons with a certain 230 condition, by multiplying the estimated number of US individuals living with the condition (CDC, 231 Division of Population Health, n.d.; Dhana et al., 2023; Rajan et al., 2021; U.S. Cancer Statistics 232 Working Group, released in November 2023) by the reported SARS-CoV-2 seroprevalence at 233 the end of our study period (December 2020 for the national, or after each wave for the state 234 data)(Centers for Disease Control and Prevention, 2023). We focused on seroprevalence 235 among individuals ≥65 years, the most relevant age group for the conditions we considered (we 236 also run a sensitivity analysis considering seroprevalence in adults 50-64 years, see 237 discussion). We then multiplied the estimated number of SARS-CoV-2 infections by an age-238 specific infection-fatality ratio (IFR) for SARS-CoV-2 (COVID-19 Forecasting Team, 2022). This 239 gave an estimate of COVID-19-related deaths, or excess deaths, for a given condition. To 240 estimate a percent elevation over baseline and compare with our vital statistics analysis, we 241 divided the excess death estimate derived from the demographic model by the total deaths for 242 that condition for a similar period of time in 2019 (see Methods). We repeated this analysis for 243 each cancer type, diabetes, and Alzheimer's. In addition to the null hypothesis, we also 244 projected alternative hypotheses of a biological association between chronic conditions and 245 COVID-19, assuming that a given chronic condition would raise the risk of COVID-19 mortality 246 (via the infection fatality ratio) by a factor of 2 or 5. We compared these modeled expectations 247 for the null and alternative hypotheses with the observed excess mortality in 2020, using MC 248 mortality as the outcome (Table 2).

249 Under the null hypothesis we projected a 0-2% elevation over the 2019 baseline in deaths for all 250 cancer types in national data, and 0-9% elevations in state-level data (Table 3). Under the 251 alternative hypothesis that cancer increases COVID-19 mortality risk by a factor of 2, the 252 projected elevation is 0-5% in national data and 0-18% in state-level data. In general, the largest 253 projected increases were found in NY state, driven by the higher attack rates. We also see 254 systematic differences in the percent elevation over baseline by type of cancer, related to the 255 lethality of different cancers. For instance, even if cancer increases COVID-19 mortality risk by a 256 factor of 2, we expect to see only a 0-1% increase for particularly deadly cancers such as 257 pancreatic and lung cancer, in part driven by the high competing risk of death from these 258 cancers (short life expectancy) and the small size of the population-at-risk. The expected 259 increases for less deadly cancers, such as colorectal and breast, were notably higher (2-5% in 260 national data, and 9-18% during the large spring wave in New York), in part driven by the lower

risk of death from these cancers (longer life expectancy). Based on the observations from our
time series analysis of MC mortality in all states, non-hematological cancers are most consistent
with a 1- to 2-fold increase in mortality, with the caveat that most of the confidence intervals
include zero, and the differences in projected mortality under these hypotheses are minimal. In
contrast, for hematological cancer, the observed rise in mortality exceeds the expected
elevation even under the assumption of a 5-fold increase in mortality.

267 We repeated this analysis for diabetes and Alzheimer's (Table 3). For diabetes under the null 268 hypothesis, we projected an 8% elevation over baseline in national data and 12-30% in state-269 level data based on the age distribution and substantial size of the population-at-risk alone. In 270 fact, we observed in vital statistics analysis a 37% elevation over baseline in national US data 271 and 59-128% in state-level data, with the largest increase seen in NY and lowest increase in 272 CA. These observations are most consistent with a 5-fold increase in mortality based on our 273 demographic model (projected elevation 40% nationally and 62-148% at the state level). For 274 Alzheimer's under the null hypothesis, we projected a 28% increase over baseline nationally, 275 and 30-191% increases at the state level, largely driven by the advanced age of the population-276 at-risk. In contrast, analysis of vital statistics data reveals a 19% increase nationally and 18-49% 277 across states, which is in fact lower than the null hypothesis (we return to this surprising result in 278 the discussion). Strikingly, our demographic model supports that COVID-19 will manifest 279 differently in population-level excess mortality for each of these chronic conditions, even under 280 the null hypothesis of no biological association between viral infection and these underlying 281 comorbidities. Overall, these projections support the idea that demography alone (age, size, and 282 baseline mortality of the population living with each of these conditions) can explain much of the 283 differences in absolute and relative mortality elevations seen during the pandemic across

284 conditions like cancer, diabetes, and Alzheimer's.

#### 285 Discussion

286 Cancer is generally thought of as a risk factor for severe COVID-19 outcomes, yet observational 287 studies have produced conflicting evidence. With recent availability of more detailed US vital 288 statistics data, we used statistical time series approaches to generate excess mortality 289 estimates for multiple cause of death data, different types of cancer, and several geographic 290 locations during 2020. We accounted for potential changes in coding practices during the 291 pandemic, for instance capturing a COVID-19 patient with cancer whose death may have been 292 coded as an underlying COVID-19 death and not a cancer death. Based on multiple cause of 293 death data, we estimated 13.600 national COVID-19-related excess cancer deaths, which aligns 294 well with reporting on death certificate data, where 13,400 deaths are ascribed to COVID-19 in 295 cancer patients (Appendix 1 - Figure 9) (Fedeli et al., 2024). Yet these deaths only represent a 296 3% elevation over the expected baseline cancer mortality. Percent mortality elevation was 297 measurably higher for less deadly cancers (breast and colorectal) than cancers with a poor 5-298 year survival (lung and pancreatic). Consistent with other studies (Chavez-MacGregor et al., 299 2022; S. Han et al., 2022; Rüthrich et al., 2021; Williamson et al., 2020), we found that the 300 largest mortality increase for specific cancer types was seen in hematological cancers with a 7% 301 elevation over baseline in national data. Across the board, the largest elevations in cancer

302 mortality were observed in the states most impacted by the first year of the COVID-19 pandemic 303 (e.g., NY), lending support to the specificity of our excess mortality approach.

304 In contrast to cancer, we observed substantial COVID-19-related excess mortality for diabetes 305 and Alzheimer's, temporally and geographically consistent with the three-wave "signature" 306 pattern observed in reported COVID-19 cases and deaths across the US. To investigate 307 whether demographic differences in underlying patient populations (age distribution, population 308 size, and baseline risk of death due to chronic condition) could explain differences in excess 309 mortality during the pandemic, we ran a simple demographic model for each condition - first 310 assuming the condition in and of itself was not a risk factor for COVID-19-related mortality (null 311 hypothesis). Doing so we found that the rise in cancer deaths during COVID-19 was expected to 312 remain low compared to these other chronic conditions, largely driven by the higher risk of death 313 from cancer itself compared to diabetes and Alzheimer's. These demographic projections 314 illustrate the importance of competing risks (Figure 6), where the risk of cancer death 315 predominates over the risk of COVID-19 death in 2020. This is exacerbated in cancers with high 316 mortality rates. For instance, even if pancreatic cancer had in fact doubled the risk of dying of 317 COVID-19 (IFR = 4.2% vs. 2.1%), we would only expect a rise in excess mortality around 0.4%318 during the pandemic (Table 3), while the 2019 baseline risk of death for pancreatic cancer itself 319 is over 60% (Figure 6). On the other hand, for conditions with a lower baseline level mortality,

320 such as diabetes, we expect substantial COVID-19 driven elevations in mortality.

321 Our analysis revealed interesting differences between types of cancers. Both nationally and at 322 the state-level, the observed excess mortality for non-hematological cancers was consistent 323 with a 1- to 2-fold increase in COVID-19 mortality risk in patients with these types of cancer. 324 Importantly, our analysis ignores any behavioral effects associated with the pandemic. It is 325 conceivable that cancer patients may have shielded themselves from COVID-19 more than the 326 average person in 2020. Our projections assume an average risk of infection for a typical 327 individual over 65 years as there is no serologic data on infection attack rates for specific clinical 328 population subgroups (of any age). If shielding from exposure to SARS-CoV-2 was high among 329 cancer patients, our projections of cancer excess mortality during the pandemic would be 330 inflated. In other words, if shielding was particularly pronounced, cancer may conceivably be a 331 higher risk factor than shown here. Retrospective serologic analysis of banked sera from the 332 first year of the pandemic, broken down by underlying comorbidities, may shed light on whether 333 infection risk may have varied by chronic condition.

334 State-level mortality patterns can potentially provide complementary insights on the question of 335 shielding. Because NY state experienced the earliest and most intense COVID-19 wave of the 336 US, with over 20% of the population infected in Spring 2020 (Stadlbauer et al., 2021), and 337 because social distancing did not come into effect until March 2020, shielding would have had a 338 more limited impact there than in other states. Thus, a biological relationship between cancer 339 and COVID-19 would have been most dramatic in NY in spring 2020. Indeed, cancer excess 340 mortality was exacerbated in NY, including an 9-16% increase in colorectal and breast cancer 341 mortality, consistent with a 2-fold increase in COVID-19 mortality risk from these cancers, and a 342 10% increase in hematological cancers, consistent with a 5-fold increase in COVID-19 mortality 343 risk. In NY, the absence of excess mortality in lethal cancers, such as pancreatic and lung

344 cancers (1% over baseline) are, as discussed above, still consistent with what would be345 expected under a high competing risk situation.

346 We used diabetes and Alzheimer as positive controls for a known biological association 347 between COVID-19 and chronic conditions. Diabetes stood out in our analyses with the highest 348 absolute and relative increases in excess mortality during the pandemic. The magnitude of the 349 mortality increases, both nationally and at the state level, were close to what would be expected 350 if diabetes increased COVID-19 mortality by 5-fold. Many studies have shown that diabetes 351 increases the risk of COVID-19 mortality, with an effect size around 2 (Williamson et al. 2020; 352 Huang et al. 2020; Kastora et al. 2022). Impaired immune function and chronic inflammation 353 have been identified as mechanisms driving poor outcomes for diabetes patients (Figueroa-354 Pizano et al. 2021). The discrepancy between the observed excess and our expectations may 355 come down to uncertainty in the SARS-CoV-2 infection rates assumed in our demographic 356 model. The population living with diabetes is slightly younger than that of the other conditions 357 (mean age, 58-60 years), while we used serologic infection rates reported for individuals over 358 65 years in our main analysis. The SARS-CoV-2 attack-rate among those 50-64 years was 359 10.1% at the end of 2020, compared to 6.3% in individuals over 65 (Centers for Disease Control 360 and Prevention, 2023). A sensitivity analysis using this higher attack rate in our demographic 361 model lends more support to the hypothesis that diabetes increases COVID-19 mortality by 2-362 fold, rather than 5-fold as found in our main analysis.

363 Our second positive control, Alzheimer's, revealed surprising results. Although we observed 364 significant excess mortality in MC Alzheimer's data, it was still less than expected under the null 365 hypothesis that Alzheimer's was not a risk factor for COVID-19 mortality. This is unexpected in 366 light of several observational studies that have shown Alzheimer's to be a risk factor (Tahira et 367 al., 2021; Wang et al., 2021; Zhang et al., 2021). As with cancer and diabetes, there is uncertainty in the SARS-CoV-2 infection rates used in the demographic model, due to the 368 369 potential effect of shielding and the age-specific SARS-CoV-2 infection risk of the Alzheimer's 370 population. We estimated that the average age of the population living with Alzheimer's disease 371 was 80-81 years, and the infection rates for the general population over 65 years may not 372 accurately reflect exposure in this subpopulation. Decreasing the attack rates by 20-30% (down 373 to 4.4-5.0%) puts the observed estimates in the range of the expectations under the null 374 hypothesis. Overall, given uncertainty in SARS-CoV-2 attack-rates and the age and size of the 375 population-at-risk for all studied conditions, our demographic model projections are not an exact 376 tool to titrate excess mortality nor the relative risk associated with each condition. Our model 377 merely serves as an illustration of the role of demography and competing risks.

378 Most vital statistics studies of the COVID-19 pandemic have relied on underlying cause-specific 379 deaths, which are prone to changes in coding practices. Our initial hypothesis going into this 380 work was that coding changes associated with a better recognition of the impact of SARS-CoV-381 2 led to an underestimation of excess mortality from cancer, affecting our perception of the 382 relationship between cancer and COVID-19. We certainly found an effect of coding changes, 383 where for instance a drop in excess mortality in underlying cancer deaths turned into an 384 increase in multiple-cause (any-listed) cancer deaths, particularly in the first COVID-19 385 pandemic wave. A similar observation was made by Fedeli et al. The impact of coding changes

was also seen in mortality from other chronic conditions but was particularly important for
 cancer. Yet both the absolute and relative excess mortality elevation remained modest for
 cancer, even after adjustment for coding changes, highlighting the importance of additional
 mechanisms such as competing mortality risks between COVID-19 and cancer.

390 An interesting hypothesis was put forward 20 years ago proposing that immunosuppression 391 from cancer may explain the lack of excess cancer mortality in the 1968 influenza pandemic -392 the immune incompetence rescue hypothesis (Reichert et al 2004). This hypothesis contends 393 that it is a detrimental immune response that leads to influenza death. A similar hypothesis was 394 put forward to explain the extreme mortality in young healthy adults in the 1918 pandemic (Short 395 et al., 2018). However, observational studies have found that patients with hematological 396 cancers have twice the risk of dying compared to patients without cancer, likely due to the 397 immunosuppression associated with their malignancy and treatment (X. Han et al., 2022; 398 Starkey et al., 2023; Williamson et al., 2020). Under the immune incompetence rescue 399 hypothesis, hematological cancers would be expected to have the lowest excess mortality of all 400 types of cancers. Our excess mortality analysis reveals instead that hematologic cancers were 401 the most impacted by the pandemic, relative to other types of cancer, with observed mortality 402 patterns consistent with a 5-fold increase in risk of COVID-19 death in patients with 403 hematological cancers. Overall, we do not find any support for the immune competence rescue

404 hypothesis.

405 Our study is subject to limitations. First, we did not study the potential long-term consequences 406 of the pandemic on cancer care, which may have resulted in avoidance of the health care 407 system for diagnosis or treatment. We did not see any delayed pandemic effect on mortality 408 from pancreatic cancer, which may have manifested in 2020 given the very low survival rate of 409 this cancer (Lemanska et al., 2023), but we cannot rule out longer-term effects on breast or 410 colorectal cancers that would not be seen until 2021 or later (Doan et al., 2023; Han et al., 2023; 411 Haribhai et al., 2023; R. Lee et al., 2023; Nascimento de Lima et al., 2023; Nickson et al., 2023; 412 Nonboe et al., 2023; Tope et al., 2023). Interestingly, in the US, all-cause underlying cancer 413 mortality rates do not appear to rise between 2020 and 2023 (Appendix 1 - Figure 10), but data 414 prior to the pandemic show a rise in cancer incidence, largely driven by increasing cancer rates 415 in younger adults (Zhao et al. 2023; Siegel et al. 2024). Additional years of data will be 416 important to evaluate the long-term impacts of the COVID-19 pandemic and these changing 417 demographics on cancer mortality rates. Additional years of data will also be important for 418 assessing the impact of vaccination on the relationship between cancer and COVID-19; there is 419 evidence that vaccines may be less immunogenic in patients with cancer compared to those 420 without (Seneviratne et al., 2022). Another limitation of our study is the reliance on mortality as 421 an outcome, and not the risk of COVID-19-related hospitalization and morbidity, and Long 422 COVID in cancer patients. A small US study reported that 60% of cancer patients suffered Long 423 COVID symptoms (Dagher et al., 2023). Future analyses using hospitalization data and 424 electronic medical records may provide additional insights on how different cancer stages or 425 other comorbidities may contribute to increased risk of severe COVID-19 outcomes. Lastly, a 426 few methodological limitations are worth raising. Though it was important to assess excess 427 mortality in state level data because of asynchrony in pandemic waves, confidence intervals in 428 state-level estimates were large, particularly for specific types of cancers, affecting significance

- 429 levels. Additional methodological limitations relate to our demographic model, especially as
- regards assumptions about SARS-CoV-2 infection rates in populations of different ages and
- with different chronic conditions. Importantly, our conclusions regarding the importance of
   competing risks are robust to these assumptions. Lastly, our study is a time-trend analysis ar
- 432 competing risks are robust to these assumptions. Lastly, our study is a time-trend analysis and
  433 like cohort and case-control studies correlation does not necessarily imply causation.
- However, the intensity and brevity of COVID-19 pandemic waves in space and time lends
- 435 support to our analyses.

# 436 Conclusion

- 437 Our detailed excess mortality study considered six cancer types and found that there is at most
- a modest elevation in cancer mortality during the COVID-19 pandemic in the US. Our results
- 439 demonstrate the importance of considering multiple-causes-of-death records to accurately
- reflect changes in coding practices associated with the emergence of a new pathogen. In
- 441 contrast to earlier studies, we propose that lack of excess cancer mortality during the COVID-19
- 442 pandemic reflects the competing mortality risk from cancer (especially for deadly types like
- 443 pancreatic and lung cancers) itself rather than protection conferred from immunosuppression.
- We note the more pronounced elevation in mortality from hematological cancers during the
- pandemic, compared to other cancers and to expectations from a demographic model, which
- aligns with a particular group of cancer patients singled out in several cohort studies. Future
- research on the relationship between COVID-19 and cancer should concentrate on additional
- 448 outcomes, such as excess hospitalizations, Long COVID, changes in screening practices during
- 449 COVID-19, and longer-term patterns in cancer mortality.

# 450 Materials and Methods

# 451 Data sources

452 US National vital statistics.

We obtained individual ICD-10 coded death certificate data with exact date of death from the 453 454 United States for the period January 1, 2014, to December 31, 2020. Each death certificate has 455 one underlying cause (UC) of death, defined as the disease or injury that initiated the train of 456 events leading directly to death, and up to twenty causes of death in total, referred to here as 457 multiple cause mortality (MC). We considered 10 conditions, including diabetes, Alzheimer's 458 disease, ischemic heart disease (IHD), kidney disease, and 6 types of cancer (all-cause cancer, 459 colorectal, breast, pancreatic, lung, and hematological; see Table 1 and Appendix 1 - Table 1 460 for a list of disease codes). We chose these types of cancer to illustrate conditions for which the 5- year survival rate is low (13% and 25%, respectively, for pancreatic and lung cancers) and 461 462 high (65% and 91%, respectively, for colorectal and breast cancers) (National Cancer Institute, 463 n.d.). Hematological cancer (67% 5-year survival) was included because it was singled out as a 464 risk factor by previous studies. We compiled time series by week, geography (aggregated 465 National, NY, TX, and CA) and cause of death, separately for underlying and multiple cause 466 mortality.

- 467 To observe longer-term trends in later years of the COVID-19 pandemic, we downloaded
- 468 aggregated weekly-level data from 2021 to 2023 for all-cause cancer, diabetes, and Alzheimer's469 disease from CDC Wonder.
- 470 Estimated populations living with each chronic condition.
- 471 We estimated the size of the population-at-risk for all-cause and specific cancers using the 5-
- 472 year limited duration prevalence estimates provided by the U.S. Cancer Statistics webpage
- 473 (U.S. Cancer Statistics Working Group ...). Estimates for diabetes were drawn from CDC's
- 474 Behavioral Risk Factor Surveillance System Chronic Disease Indicators (CDC, Division of
- 475 Population Health). Estimates for Alzheimer's disease were taken from publications from the
- 476 Alzheimer's Association (Rajan et al. 2021; Dhana et al. 2023).
- 477 For each condition, age-specific prevalence data were tabulated for the US and for each state
- 478 separately. For cancer, age-level data were only available at the national level so these age-
- 479 specific prevalence estimates were applied to the populations for each of the three states
- 480 considered (NY, CA, TX). Age-level data were provided for all ages for cancer (<20 years, 20-
- 481 80 years in 10-year groupings,  $\geq$ 80 years), for adults  $\geq$  18 for diabetes (18-44years, 45-64years,
- 482  $\geq$  65 years) and for adults  $\geq$  65 for Alzheimer's disease (65-74 years, 75-84 yrs,  $\geq$  85 years). A
- weighted mean age for the population-at-risk for each condition was calculated using the mid-point for each age group.
- 485 Other data sources
- 486 To compare vital statistics patterns with COVID-19 surveillance data, we accessed national and 487 state counts of laboratory-confirmed COVID-19 cases in 2020, from the CDC (Centers for
- 488 Disease Control and Prevention, 2022).
- 489 To clarify the expected role of COVID-19 on excess mortality, we compiled data on the
- proportion of the population with serologic evidence of SARS-CoV-2 infection from the CDC
- dashboard (Centers for Disease Control and Prevention, 2023). We further compiled data on
- estimated age-specific infection-fatality ratios from COVID-19, provided by single year of age
- 493 (COVID-19 Forecasting Team, 2022).
- 494

# 495 Statistical approach

496 <u>Weekly excess mortality models</u>

497 Similar to other influenza and COVID-19 excess mortality studies (Islam et al., 2021; Karlinsky 498 and Kobak, 2021; W.-E. Lee et al., 2023; Msemburi et al., 2023), we established a predicted 499 baseline of expected mortality for each time series, and computed the excess mortality as the 500 excess in observed deaths over this baseline. To establish baselines for each disease nationally 501 and in each state, we applied negative binomial regression models to weekly mortality counts 502 for each cause of death, smoothed with a 5-week moving average and rounded to the nearest

- 503 integer. Models included harmonic terms for seasonality, time trends, and an offset for
- 504 population size. For each condition and location, we used Akaike Information Criterion (AIC) to
- select between three models with different time trends (see Appendix 1 Supplemental
- 506 Methods, Appendix 1- Figure 11, for the final model selection for each location and condition), 507 following:
- 508 Model 1:
- 509 Weekly\_mortality = t +  $cos(2\pi t/52.17) + sin(2\pi t/52.17) + offset(log(population))$ , where t
- 510 represents week.
- 511 Model 2:
- 512 Weekly\_mortality = t + t<sup>2</sup> +  $cos(2\pi t/52.17)$  +  $sin(2\pi t/52.17)$  + offset(log(population)), where t
- 513 represents week.
- 514 Model 3:
- 515 Weekly\_mortality = t + t2 + t3 +  $cos(2\pi t/52.17) + sin(2\pi t/52.17) + offset(log(population))$ , where t 516 represents week.
- 517 We fitted national and state-level models for each mortality outcome from January 19, 2014, to
- 518 March 1, 2020, and projected the baseline forward until December 6, 2020, the last complete
- 519 week of smoothed mortality data. Models were fitted using the MASS package in R version 4.3.

520 Using COVID-19 coded death certificates from March 1, 2020, to December 6, 2020, we 521 established the timing of each pandemic wave from trough to trough. We found that nationally, 522 the first wave occurred from March 1, 2020, to June 27, 2020; the second wave from June 28, 523 2020, to October 3, 2020, and the third from October 4, 2020, to December 6, 2020 (the 3rd 524 wave was not completed by the last week of available smoothed data on December 6, 2020). 525 For NY, the pandemic pattern was characterized by an intense first wave in Spring 2020, while 526 TX had its major wave in summer 2020 and CA in late 2020. Comparison of mortality patterns 527 from these three states provides an opportunity to separate the effect of SARS-CoV-2 infection 528 from that of behavioral changes later in the pandemic. For instance, the effects of healthcare 529 avoidance would predominate in CA or TX in Spring 2020, as there was little SARS-CoV-2 530 activity but much media attention on COVID-19, with cancer patients potentially avoiding 531 medical care out of fear of getting infected. In contrast, risk of infection would dominate in NY in 532 Spring 2020, and behavioral factors may only play a role as SARS-CoV-2 awareness increased 533 and the wave was brought under control by social distancing.

We estimated weekly excess mortality by subtracting the predicted baseline from the observed
mortality. We summed weekly estimates to calculate excess mortality for the full pandemic
period and for each of the 3 waves within the first year of the pandemic. In addition to estimating
the absolute effects of the pandemic on mortality, we also calculated relative effects by dividing
excess deaths in each diagnosis group by the model baseline. Confidence intervals on excess
mortality estimates were calculated by resampling the estimated model coefficients 10,000

times using a multivariate normal distribution and accounting for negative binomial errors inweekly mortality counts.

542 We used Pearson correlation to test synchronicity patterns in weekly excess mortality from 543 different cancers and chronic conditions to underlying COVID-19 deaths. Correlation analysis 544 assumes a direct and immediate effect of COVID-19 on cancer mortality. We also investigated 545 the possibility of delayed effects or harvesting by inspecting the time series for evidence of such 546 effects and by comparing total excess deaths for distinct pandemic waves and the whole of 547 2020.

# 548 <u>Projections of excess mortality under the null hypothesis of no specific COVID-19 mortality risk</u> 549 <u>of each condition</u>

550 To further test the impact of age on the association between chronic conditions and COVID-19 551 and clarify the additional risk due to each chronic condition, we projected the number of COVID-552 19 deaths under the null hypothesis that demographic characteristics alone (size, age, and 553 baseline mortality risk for each condition) are driving excess mortality, and that there is no 554 interaction between the condition and SARS-CoV-2 infection. Excess mortality projections were 555 then compared with observed excess mortality. We only used MC deaths for this approach to 556 account for the possibility that some individuals may suffer from multiple conditions. For 557 example, an estimated 11.5% of US adults with type 2 diabetes also have a history of cancer 558 (Yeh et al., 2018).

559 We first calculated the number of expected COVID-19 infections among persons living with a 560 certain chronic condition, by multiplying the estimated number of individuals living with the 561 condition by the reported SARS-CoV-2 seroprevalence among individuals ≥65 years at specific 562 time points during 2020. For the national data and California, we used results from the survey 563 conducted from November 23 - December 12, 2020. For New York we used estimates from the 564 survey conducted from July 27 - August 13, 2020 (the earliest data available). And for Texas we 565 used the survey conducted from October 5-19, 2020 (following the large summer wave). 566 (Centers for Disease Control and Prevention, 2023). We then multiplied this by the COVID-19 567 IFR based on the estimated mean age of individuals living with the condition (COVID-19 568 Forecasting Team, 2022) to arrive at the projected number of COVID-19-related excess deaths 569 for a particular condition during 2020. We put uncertainty intervals around these estimates using 570 the lower and upper bounds from the estimated attack-rates and COVID-19 IFRs.

571 To obtain a relative metric of expected COVID-19 burden, we divided projected COVID-19 572 excess deaths by total deaths in each diagnosis group in the 2019 baseline period (March to 573 December 2019, for the national data. For the states we used the months in 2019 574 corresponding to their large waves in 2020), resulting in an expected percentage elevation over 575 baseline in 2020. We compared this null expectation to the observed percentage elevation over 576 baseline from our excess mortality models. We also generated the expected number of excess 577 deaths under alternative hypotheses where each condition is associated with a 2- or 5-fold 578 increased risk of COVID-19 related death given infection (i.e., the baseline age-adjusted 579 infection fatality ratio used in the null hypothesis was increased 2- or 5-fold).

- 580 The equation for the expected percent increase in excess mortality over baseline deaths under
- the null hypothesis, for a specific risk condition (cancer, diabetes., Alzheimer) and time-period,can be written as:
- 583 Expected percent increase in excess mortality for a chronic condition and time period = (size of 584 population-at-risk for the condition \* SARS-CoV-2 infection rate for the period \* age-specific
- 585 IFR) / baseline mortality for the condition in comparable period in 2019
- 586 The expected mortality increases under the alternative hypothesis of a 2- or 5-fold increased
- risk of COVID-19 death from the condition under study is modeled by multiplying the right-hand
- side of the above equation by the increased risk (i.e., we assume that presence of the
- underlying condition will increase the IFR by 2- or 5-fold compared to the IFR for the generalpopulation).

# 591 Acknowledgements

592 This paper is dedicated to our colleague Robert J Taylor who succumbed to cancer in 2022 and 593 who wanted to know if a cancer diagnosis was a COVID-19 mortality risk factor.

# 594 Additional Information

- 595 Funding
- 596 LS acknowledges funding from the Carlsberg Foundation, grant number CF20-0046. LS and
- 597 CLH acknowledge funding from Danish National Research Foundation (grant number
- 598 DNRF170) for the PandemiX Center of Excellence. CLH has received contract-based hourly
- 599 consulting fees from Sanofi outside of the submitted work.
- 600 Author contributions
- 601 Chelsea Hansen, Data curation, Formal analysis, Visualization, Methodology, Writing original
- draft, Writing review and editing; Cécile Viboud, Data curation, Formal analysis, Visualization,
- 603 Methodology, Writing original draft, Writing review and editing; Lone Simonsen,
- 604 Conceptualization, Data curation, Formal analysis, Visualization, Methodology, Writing original
- 605 draft, Writing review and editing
- 606 Author ORCIDs
- 607 Chelsea L Hansen: https://orcid.org/0000-0002-4526-6772
- 608 Cécile Viboud: http://orcid.org/0000-0003-3243-4711
- 609 Lone Simonsen: http://orcid.org/0000-0003-1535-8526
- 610 Data availability
- 611 Individual-level mortality data were obtained from the National Center for Healthcare Statistics.
- 612 These data are not publicly available due to privacy concerns, but descriptive characteristics
- 613 have been summarized in Table 1 and Appendix Table 1. The excess mortality models in this

- 614 paper use mortality data aggregated by week and US state. These data, along with the model
- 615 code, have been posted to the following public GitHub repository: <u>https://github.com/chelsea-</u>
- 616 <u>hansen/Disentangling-the-relationship-between-cancer-mortality-and-COVID-19</u>
- 617 Additional weekly, aggregated mortality data are publicly available through CDC Wonder.
- Data used for the demographic model, along with the code have also been posted to the GitHubrepository.
- 620 Weekly, state-level data on recorded COVID-19 cases and deaths are publicly available. Data
- 621 were downloaded from here: <u>https://data.cdc.gov/Case-Surveillance/Weekly-United-States-</u>
- 622 <u>COVID-19-Cases-and-Deaths-by-/pwn4-m3yp</u> and have also been posted as a .csv file to the 623 GitHub repository referenced above.
- 624 Disclaimer
- 625 This article represents the views of the authors and not necessarily those of the National
- 626 Institutes of Health or the US government.

### 627 References

- Alicandro G, La Vecchia C, Islam N, Pizzato M. 2023. A comprehensive analysis of all-cause
   and cause-specific excess deaths in 30 countries during 2020. *Eur J Epidemiol.* doi:10.1007/s10654-023-01044-x
- 631 CDC, Division of Population Health. n.d. Chronic disease indicators. Diabetes among adults.
   632 https://cdi.cdc.gov/?location=US&category=DIA&indicators=DIA01
- 633 Centers for Disease Control and Prevention. 2023. COVID-19 serology surveillance. 634 https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology.html
- 635 Centers for Disease Control and Prevention. 2022. Weekly United States COVID-19 cases and 636 deaths by state - ARCHIVED.
- 637 Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. 2022. Evaluation of COVID-19
   638 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol
   639 8:69–78.
- 640 COVID-19 Forecasting Team. 2022. Variation in the COVID-19 infection-fatality ratio by age,
   641 time, and geography during the pre-vaccine era: a systematic analysis. *Lancet* 399:1469–
   642 1488.
- Dagher H, Chaftari A-M, Subbiah IM, Malek AE, Jiang Y, Lamie P, Granwehr B, John T, Yepez
  E, Borjan J, Reyes-Gibby C, Flores M, Khawaja F, Pande M, Ali N, Rojo R, Karp DD,
  Chaftari P, Hachem R, Raad II. 2023. Long COVID in cancer patients: preponderance of
  symptoms in majority of patients over long time period. *Elife* 12. doi:10.7554/eLife.81182
- bhana K, Beck T, Desai P, Wilson RS, Evans DA, Rajan KB. 2023. Prevalence of Alzheimer's
   disease dementia in the 50 US states and 3142 counties: A population estimate using the
   2020 bridged-race postcensal from the National Center for Health Statistics. *Alzheimers Dement* 19:4388–4395.
- Di Felice G, Visci G, Teglia F, Angelini M, Boffetta P. 2022. Effect of cancer on outcome of
   COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated
   patients. *Elife* 11. doi:10.7554/eLife.74634
- Doan C, Li S, Goodwin JS. 2023. Breast and Lung Cancer Screening Among Medicare
   Enrollees During the COVID-19 Pandemic. JAMA Netw Open 6:e2255589.
- 656 Fedeli U, Amidei CB, Han X, Jemal A. 2024. Changes in cancer-related mortality during the

657 COVID-19 pandemic in the United States. *JNCI* 116(1): 167-169. Doi:10.1093/jnci/djad191. 658 Fernandes GA, Junior APN, Azevedo E Silva G, Feriani D, França E Silva ILA, Caruso P,

- 659 Curado MP. 2021. Excess mortality by specific causes of deaths in the city of São Paulo, 660 Brazil, during the COVID-19 pandemic. *PLoS One* **16**:e0252238.
- Gobiņa I, Avotiņš A, Kojalo U, Strēle I, Pildava S, Villeruša A, Briģis Ģ. 2022. Excess mortality
  associated with the COVID-19 pandemic in Latvia: a population-level analysis of all-cause
  and noncommunicable disease deaths in 2020. *BMC Public Health* 22:1109.
- Grande E, Fedeli U, Pappagallo M, Crialesi R, Marchetti S, Minelli G, Iavarone I, Frova L, Onder
   G, Grippo F. 2022. Variation in Cause-Specific Mortality Rates in Italy during the First Wave
   of the COVID-19 Pandemic: A Study Based on Nationwide Data. Int J Environ Res Public
   Health 19. doi:10.3390/ijerph19020805
- Han S, Zhuang Q, Chiang J, Tan SH, Chua GWY, Xie C, Chua MLK, Soon YY, Yang VS. 2022.
  Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic
  review and meta-analysis. *BMJ Open* 12:e044661.
- Han X, Hu X, Zhao J, Jemal A, Yabroff KR. 2022. Identification of Deaths Caused by Cancer
   and COVID-19 in the US During March to December 2020. JAMA Oncol 8:1696–1698.
- Han X, Yang NN, Nogueira L, Jiang C, Wagle NS, Zhao J, Shi KS, Fan Q, Schafer E, Yabroff
  KR, Jemal A. 2023. Changes in cancer diagnoses and stage distribution during the first
  year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment. *Lancet Oncol* 24:855–867.
- Haribhai S, Bhatia K, Shahmanesh M. 2023. Global elective breast- and colorectal cancer
  surgery performance backlogs, attributable mortality and implemented health system
  responses during the COVID-19 pandemic: A scoping review. *PLOS Glob Public Health*3:e0001413.
- Islam N, Shkolnikov VM, Acosta RJ, Klimkin I, Kawachi I, Irizarry RA, Alicandro G, Khunti K,
  Yates T, Jdanov DA, White M, Lewington S, Lacey B. 2021. Excess deaths associated with
  covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high
  income countries. *BMJ* 373:n1137.
- Karlinsky A, Kobak D. 2021. Tracking excess mortality across countries during the COVID-19
   pandemic with the World Mortality Dataset. *Elife* 10. doi:10.7554/eLife.69336
- Kontopantelis E, Mamas MA, Webb RT, Castro A, Rutter MK, Gale CP, Ashcroft DM, Pierce M,
  Abel KM, Price G, Faivre-Finn C, Van Spall HGC, Graham MM, Morciano M, Martin GP,
  Sutton M, Doran T. 2022. Excess years of life lost to COVID-19 and other causes of death
  by sex, neighbourhood deprivation, and region in England and Wales during 2020: A
  registry-based study. *PLoS Med* **19**:e1003904.
- Lee R, Xu W, Dozier M, McQuillan R, Theodoratou E, Figueroa J, UNCOVER and the
  International Partnership for Resilience in Cancer Systems (I-PaRCS), Breast Cancer
  Working Group 2. 2023. A rapid review on the COVID-19's global impact on breast cancer
  screening participation rates and volumes from January-December 2020. *Elife* 12.
  doi:10.7554/eLife.85680
- Lee W-E, Woo Park S, Weinberger DM, Olson D, Simonsen L, Grenfell BT, Viboud C. 2023.
  Direct and indirect mortality impacts of the COVID-19 pandemic in the United States, March
  1, 2020 to January 1, 2022. *Elife* 12. doi:10.7554/eLife.77562
- Lemanska A, Andrews C, Fisher L, Bacon S, Frampton AE, Mehrkar A, Inglesby P, Davy S,
  Roberts K, Patalay P, Goldacre B, MacKenna B, OpenSAFELY Collaborative, Walker AJ.
  2023. Healthcare in England was affected by the COVID-19 pandemic across the
  pancreatic cancer pathway: A cohort study using OpenSAFELY-TPP. *Elife* 12.
  doi:10.7554/eLife.85332
- Lundberg CE, Santosa A, Björk J, Brandén M, Cronie O, Lindgren M, Edqvist J, Åberg M, Adiels
   M, Rosengren A. 2023. Age and sex differences in cause-specific excess mortality and
   years of life lost associated with COVID-19 infection in the Swedish population. *Eur J Public*

- 708 Health. doi:10.1093/eurpub/ckad086
- Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. 2023. The
  WHO estimates of excess mortality associated with the COVID-19 pandemic. *Nature*613:130–137.
- Nascimento de Lima P, van den Puttelaar R, Hahn AI, Harlass M, Collier N, Ozik J, Zauber AG,
   Lansdorp-Vogelaar I, Rutter CM. 2023. Projected long-term effects of colorectal cancer
   screening disruptions following the COVID-19 pandemic. *Elife* 12. doi:10.7554/eLife.85264
- 715 National Cancer Institute. n.d. Cancer stat facts. SEER. https://seer.cancer.gov/statfacts/
- 716 Nickson C, Smith MA, Feletto E, Velentzis LS, Broun K, Deij S, Grogan P, Hall M, He E, St John
- DJ, Lew J-B, Procopio P, Simms KT, Worthington J, Mann GB, Canfell K. 2023. A modelled
  evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening
  programmes in Australia. *Elife* 12. doi:10.7554/eLife.82818
- Nonboe MH, Napolitano G, Schroll JB, Vejborg I, Waldstrøm M, Lynge E. 2023. Impact of
   COVID-19 pandemic on breast and cervical cancer screening in Denmark: A register-based
   study. *Elife* 12. doi:10.7554/eLife.81605
- Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle
  A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S,
  Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi
  J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR,
  Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P,
  Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García AG, Puchol CT, Lee DG,
- Slavin M, Teh B, Arias CA, Data-Driven Determinants for COVID-19 Oncology Discovery
   Effort (D3CODE) Team, Kontoyiannis DP, Malek AE, Chaftari A-M. 2023. International
   multicenter study comparing COVID-19 in patients with cancer to patients without cancer:
   Impact of risk factors and treatment modalities on survivorship. *Elife* 12.
   doi:10.7554/eLife.81127
- Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. 2021. Population
  estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the
  United States (2020-2060). *Alzheimers Dement* 17:1966–1975.
- Rüthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Grüner B, Hanses F, Isberner
  N, Köhler P, Lanznaster J, Merle U, Nadalin S, Piepel C, Schneider J, Schons M, Strauss
  R, Tometten L, Vehreschild JJ, von Lilienfeld-Toal M, Beutel G, Wille K, LEOSS Study
  Group. 2021. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis
- 740 Group. 2021. COVID-19 in carcer patients. clinical characteristics and outcome-an ana 741 of the LEOSS registry. *Ann Hematol* **100**:383–393.
- Seneviratne SL, Yasawardene P, Wijerathne W, Somawardana B. 2022. COVID-19 vaccination
   in cancer patients: a narrative review. *J Int Med Res* 50:3000605221086155.
- Short KR, Kedzierska K, van de Sandt CE. 2018. Back to the Future: Lessons Learned From
   the 1918 Influenza Pandemic. *Front Cell Infect Microbiol* 8:343.
- Silversmit G, Verdoodt F, Van Damme N, De Schutter H, Van Eycken L. 2021. Excess Mortality
   in a Nationwide Cohort of Cancer Patients during the Initial Phase of the COVID-19
   Pandemic in Belgium. *Cancer Epidemiol Biomarkers Prev* 30:1615–1619.
- Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA,
   McMahon M, Capuano C, Twyman K, Jhang J, Nowak MD, Simon V, Sordillo EM, van
   Bakel H, Krammer F. 2021. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in
   New York City. *Nature* 590:146–150.
- Starkey T, Ionescu MC, Tilby M, Little M, Burke E, Fittall MW, Khan S, Liu JKH, Platt JR, Mew
  R, Tripathy AR, Watts I, Williams ST, Appanna N, Al-Hajji Y, Barnard M, Benny L, Burnett
  A, Bytyci J, Cattell EL, Cheng V, Clark JJ, Eastlake L, Gerrand K, Ghafoor Q, Grumett S,
  Harper-Wynne C, Kahn R, Lee AJX, Lomas O, Lydon A, Mckenzie H, NCRI Consumer
  Forum, Panneerselvam H, Pascoe JS, Patel G, Patel V, Potter VA, Randle A, Rigg AS,
  Robinson TM, Roylance R, Rogues TW, Rozmanowski S, Roux RL, Shah K, Sheehan R,

- Sintler M, Swarup S, Taylor H, Tillett T, Tuthill M, Williams S, Ying Y, Beggs A, Iveson T,
  Lee SM, Middleton G, Middleton M, Protheroe A, Fowler T, Johnson P, Lee LYW. 2023. A
  population-scale temporal case-control evaluation of COVID-19 disease phenotype and
  related outcome rates in patients with cancer in England (UKCCP). *Sci Rep* 13:11327.
- Tahira AC, Verjovski-Almeida S, Ferreira ST. 2021. Dementia is an age-independent risk factor
   for severity and death in COVID-19 inpatients. *Alzheimers Dement* 17:1818–1831.
- Tope P, Farah E, Ali R, El-Zein M, Miller WH, Franco EL. 2023. The impact of lag time to cancer
   diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping
   review of systematic reviews and meta-analyses. *Elife* 12. doi:10.7554/eLife.81354
- U.S. Cancer Statistics Working Group. released in November 2023. U.S. Cancer Statistics Data
   Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of
   Health and Human Services, Centers for Disease Control and Prevention and National
   Cancer Institute. https://www.cdc.gov/cancer/dataviz
- Wang Q, Davis PB, Gurney ME, Xu R. 2021. COVID-19 and dementia: Analyses of risk,
  disparity, and outcomes from electronic health records in the US. *Alzheimers Dement* **17**:1297–1306.
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A,
  Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ,
  Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R,
  Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. 2020. Factors
  associated with COVID-19-related death using OpenSAFELY. *Nature* 584:430–436.
- Yeh H-C, Golozar A, Brancati FL. 2018. Cancer and Diabetes In: Cowie CC, Casagrande SS,
  Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E,
  Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M,
  Fradkin JE, editors. Diabetes in America. Bethesda (MD): National Institute of Diabetes and
  Digestive and Kidney Diseases (US).
- Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Kim Y, Ogilvie AC, Narayanan NS. 2021.
   COVID-19 case fatality and Alzheimer's disease. J Alzheimers Dis 84:1447–1452.

787

**Table 1.** Each diagnosis group and its corresponding ICD-10 codes, number of underlying deaths, mean age in years at time of
 death, the percentage of deaths occurring at home, and the percentage of deaths occurring in nursing homes for 2019 and 2020.

Year	Diagnosis Group	ICD-10 Codes	No. Deaths	Mean age, years (IQR)	%Home/ER	%Nursing Home
2019	Cancer	C00-C99	493,397	72 (64-81)	45	12
	Pancreatic Cancer	C25	37,864	72 (64-80)	51	9
	Colorectal Cancer	C18-C20	42,484	71 (61-82)	46	13
	Hematologic Cancers	C81-C96	47,174	74 (67-84)	35	11
	Diabetes	E10-E14	70,763	72 (63-82)	53	17
	Alzheimer's	G30	98,675	87 (82-92)	29	50
2020	Cancer	C00-C99	513,275	72 (64-81)	55	8
	Pancreatic Cancer	C25	39,893	72 (65-80)	61	6
	Colorectal Cancer	C18-C20	43,990	71 (61-82)	56	9
	Hematologic Cancers	C81-C96	49,161	74 (67-84)	46	8
	Diabetes	E10-E14	88,124	71 (62-82)	58	15
	Alzheimer's	G30	115,256	86 (82-92)	33	46

**Table 2.** The estimated number of excess deaths and the percentage over baseline for each diagnosis group when listed as both the underlying
 cause or anywhere on the death certificate (multiple cause). Estimates for the national-level data are provided for the full pandemic period and for
 each state based on when the first large wave was experienced.

			Multiple	e Cause	Underlying Cause		
Cause of Death	State	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline	
Cancer	National	Overall	13601*	3.0	11	0.0	
	New York	1	747	6.0	-474	-5.0	
	Texas	2	467	4.0	39	0.0	
	California	3	529	4.0	82	1.0	
Pancreatic Cancer	National	Overall	-25	-0.0	-282	-1.0	
	New York	1	8	1.0	-16	-2.0	
	Texas	2	17	2.0	24	3.0	
	California	3	0	0.0	-18	-2.0	
Colorectal Cancer	National	Overall	988	2.0	-168	-0.0	
	New York	1	91	9.0	-16	-2.0	
	Texas	2	4	0.0	-34	-3.0	
	California	3	27	2.0	-1	-0.0	
Hematologic Cancers	National	Overall	3615*	7.0	111	0.0	
	New York	1	121	10.0	-107	-11.0	
	Texas	2	136	11.0	21	2.0	
	California	3	114	8.0	20	2.0	
Diabetes	National	Overall	82318*	37.0	10784*	16.0	
	New York	1	5945*	128.0	568*	40.0	
	Texas	2	4612*	77.0	420*	23.0	
	California	3	3474*	59.0	575*	33.0	
Alzheimer's	National	Overall	21712*	19.0	8528*	9.0	
	New York	1	734*	49.0	188	16.0	
	Texas	2	1398*	45.0	805*	31.0	
	California	3	726*	18.0	259	8.0	

794 \*Confidence interval does not include zero

796 Table 3. Projections of COVID-19-related excess mortality patterns for different cancers and chronic conditions in the US, 797 under different hypotheses for the association between the condition and COVID-19. Projections are provided for the null 798 hypothesis of no biological interaction between the condition and COVID-19; these projection are solely driven by the size and mean 799 age of the population living with each condition (where age determines the infection-fatality ratio from COVID-19), and the baseline 800 risk of death from the condition over a similar time period (March to December 2019 for the national data, and for the states 801 comparable dates in 2019 corresponding to the relevant COVID-19 wave). Additional projections are provided under alternative 802 hypotheses, where each condition is associated with a relative risk (RR) of 2 or 5 for COVID-19 related death (infection-fatality ratio 803 multiplied by 2 or 5).

Chronic condition	State	Population at risk	Mean age	Wave	Observed MC deaths over same period in 2019	Observed excess (% over baseline) in 2020	Expected excess (null)	Expected excess (RR=2)	Expected excess (RR=5)
All cancers	National	5718925	65	Overall	546453	3 (1-4)	1 (1-2)	2 (1-4)	6 (4-10)
	New York	400891	65	Wave 1	12244	6 (-1-15)	4 (2-10)	9 (3-20)	22 (8-51)
	Texas	397993	63	Wave 2	12187	4 (-3-11)	2 (1-6)	5 (2-12)	11 (4-29)
	California	599552	64	Wave 3	16713	4 (-1-10)	2 (0-5)	4 (1-9)	9 (2-23)
Pancreatic	National	66319	67	Overall	39798	0 (-6-7)	0 (0-0)	0 (0-1)	1 (1-2)
	New York	2584	67	Wave 1	963	1 (-21-35)	0 (0-1)	1 (0-2)	2 (1-5)
	Texas	2264	66	Wave 2	882	2 (-19-34)	0 (0-1)	0 (0-1)	1 (0-3)
	California	3482	67	Wave 3	1277	0 (-17-24)	0 (0-0)	0 (0-1)	1 (0-2)
Lung cancer	National	425015	70	Overall	123622	1 (-3-5)	1 (0-1)	1 (1-2)	3 (2-5)
	New York	17709	71	Wave 1	2643	1 (-13-20)	2 (1-4)	3 (1-8)	8 (3-20)
	Texas	12700	70	Wave 2	2513	2 (-11-20)	1 (0-2)	1 (1-4)	4 (1-9)

	California	19079	70	Wave 3	2861	3 (-10-18)	1 (0-2)	1 (0-3)	3 (1-8)
Hematological	National	459463	62	Overall	57892	7 (1-13)	1 (0-1)	1 (1-2)	3 (2-5)
	New York	15577	62	Wave 1	1305	10 (-11-40)	1 (0-3)	2 (1-5)	6 (2-13)
	Texas	14927	59	Wave 2	1231	11 (-9-38)	1 (0-1)	1 (0-3)	3 (1-7)
	California	21290	61	Wave 3	1916	8 (-8-29)	0 (0-1)	1 (0-2)	2 (1-5)
Colorectal	National	473264	66	Overall	49053	2 (-4-8)	1 (1-2)	2 (1-4)	6 (4-10)
	New York	30859	66	Wave 1	1048	9 (-13-44)	4 (2-10)	9 (3-20)	22 (8-51)
	Texas	36641	65	Wave 2	1224	0 (-18-26)	3 (1-7)	5 (2-13)	13 (4-33)
	California	51863	65	Wave 3	1575	2 (-14-24)	2 (1-5)	4 (1-10)	9 (3-24)
Breast	National	1097917	64	Overall	43519	2 (-4-9)	2 (2-4)	5 (3-8)	12 (8-21)
	New York	74459	64	Wave 1	981	16 (-8-53)	9 (3-21)	18 (7-42)	46 (17-106)
	Texas	77860	62	Wave 2	1019	3 (-17-32)	5 (2-12)	10 (3-24)	24 (8-61)
	California	123433	63	Wave 3	1421	2 (-15-25)	4 (1-10)	8 (2-20)	20 (5-51)
Diabetes	National	29105146	60	Overall	229326	37 (31-43)	8 (5-14)	16 (10-28)	40 (26-69)
	New York	1792926	60	Wave 1	4804	128 (104-158)	30 (11-68)	59 (22-136)	148 (55-340)
	Texas	2450005	58	Wave 2	5898	77 (61-96)	17 (6-44)	35 (12-87)	86 (30-218)
	California	3514440	59	Wave 3	8399	59 (47-74)	12 (3-32)	25 (7-64)	62 (17-160)
Alzheimer's	National	6070000	81	Overall	118993	19 (11-28)	28 (18-48)	57 (36-96)	142 (90-240)

New York	426500	81	Wave 1	1563	49 (23-87)	191 (70-432)	381 (140-863)	953 (350-2158)
Texas	459300	80	Wave 2	2974	45 (27-69)	63 (21-158)	126 (43-315)	315 (107-788)
California	719700	81	Wave 3	5394	18 (6-33)	39 (11-98)	78 (21-196)	195 (53-491)

Figure 1. Weekly counts of death certificates listing COVID-19 as either the underlying or a multiple cause. When included on a death certificate, COVID-19 was most often listed as the underlying cause of death rather than a contributing cause. National-level data reveal three distinct waves: Wave 1 (spring, March 1 - June 27, 2020), Wave 2 (summer, June 28 - October 3, 2020), and Wave 3 (winter, October 4 - December 6, 2020, incomplete). Vertical dashed lines represent the peak of each wave, dotted lines represent the number of reported cases (y-axis on the right). New York experienced its first large COVID-19 wave in Wave 1, while Texas had its first large wave in Wave 2 and California did not experience a large wave until Wave 3 which had not yet peaked at the end of 2020.



813

815 Figure 2. National-level weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or

816 anywhere on the death certificate (multiple cause) from 2014 to 2020. Baselines during the pandemic are projected based on the

817 previous years of data.

# National



819



### New York



Figure 4. The same as figure 1, but for Texas. Texas experienced its first large wave of COVID-19 in the summer of 2020 (Wave 2).

Texas

Figure 5. The same as figure 1, but for California. California did not experience a large wave of COVID-19 until the winter of 20202021 (Wave 3), only the first half of which is captured here.



## California

831 Figure 6. Illustration of competing risks. Based on our demographic model, we expect a small increase in cancer mortality relative to diabetes and Alzheimer's due to the higher competing risk of death from cancer compared to COVID-19. Panel a) shows the log of 832 833 the baseline mortality rate (based on observed mortality in 2019) from each condition on the x-axis and the log of the expected 834 excess mortality (elevation over baseline) on the y-axis. Chronic conditions are shown in colors while states are shown in different 835 shapes. Pancreatic cancer, the deadliest cancer considered, is on the bottom right (highest baseline mortality, lowest expected 836 excess) while diabetes and Alzheimer's are on the top left (lowest baseline mortality, highest expected excess). Panel b) shows the 837 baseline number of deaths per 100 persons at risk for each condition expected from March - December 2020 (based on deaths over 838 this same period in 2019, purple dots) compared to the expected number of deaths due to COVID-19 under the null hypothesis 839 (green dots). The null hypothesis stipulates that there is no biological association between any of these chronic diseases and COVID-19. For diabetes and Alzheimer's, the risks of baseline death and COVID-19 death are similar, while risk of death from 840 841 cancer out competes risk of COVID-19 death for all types of cancer.



#### 843 APPENDIX 1

#### 844 Supplemental Methods

845

### 846 Model selection and cross validation

847 Time series models included harmonic terms for seasonality, time trends, and an offset for 848 population size. For each condition and location, we used Akaike Information Criterion (AIC) to 849 select between three models with different time trends. The starting model (Model 1) included 850 only a linear time trend. We then tested this against a model with linear and quadratic time 851 trends (Model 2). If the AIC of Model 2 was not 2 less than Model 1, Model 1 was used as the 852 final model. If the AIC of Model 2 was 2 less than Model 1, then Model 2 was tested against a 853 model with linear, quadratic, and cubic time trends (Model 3). If the AIC of Model 3 was not 2 854 less than Model 2, then Model 2 was taken as the final model. If the AIC of Model 3 was 2 less 855 than Model 2, Model 3 was taken as the final model. The final model for each condition and 856 location was then applied to the data from 2014-2018 only and used to predict the 2019 data. 857 The coverage probability was calculated as the proportion of weeks of observed data in 2019 858 that fell within the 95% prediction interval of the time series model. The final model selected for 859 each condition and location is provided in the appendix (Appendix 1- Figure 11).

860 Characteristics of cancer, diabetes, and Alzheimer's deaths in the pre-pandemic period.

861 For each chronic condition studied (cancer, diabetes, Alzheimer's), we assessed potential 862 changes in the characteristics of deaths during the pandemic period that are unrelated to timing 863 but may signal an association with COVID-19. For instance, age is known to be a major risk 864 factor for COVID-19 mortality. For each chronic condition, we computed the average age-at-865 death in the pre-pandemic year 2019, and compared this to the average age-at-death in 2020. 866 The second potential confounder is living arrangement, as individuals living in nursing homes 867 may be at increased risk of exposure (and death) to COVID-19 due to mixing, even if their 868 underlying condition is not per se a risk factor. To test this hypothesis, we also compared the 869 proportion of individuals in each disease group who died in nursing homes in 2019 and 2020. 870 And finally, to illustrate the impact of coding practices we compared ICD-10 letter categories 871 between 2020 and 2019 for the underlying cause of death when cancer or diabetes are included 872 on the death certificate but are not listed as the underlying cause of death (Appendix 1 - Figure 873 9). For 2020, we further compared death certificates listing both COVID-19 and cancer to those 874 listing both COVID-19 and diabetes. For all comparisons between 2019 and 2020 data are 875 limited to March to December to isolate the pandemic period.

876

# 877 Supplemental tables and figures

Appendix 1 - Table 1. Diagnosis groups and corresponding ICD-10 codes, number of underlying and multiple cause deaths, mean
 age in years at time of death, the percentage of deaths occurring at home, and the percentage of deaths occurring in nursing homes
 for 2019 and 2020.

				Underlying Cause			Multiple Cause			
Year	Diagnosis group	ICD-10 codes	No. Deaths	Mean age, years (IQR)	%Home/E R	%Nursing Home	No. Deaths	Mean age, years (IQR)	%Home/E R	%Nursing Home
2019	Cancer	C00-C99	493,397	72 (64-81)	45	12	546,453	72 (64-82)	44	13
	Pancreatic Cancer	C25	37,864	72 (64-80)	51	9	39,798	72 (64-80)	50	9
	Lung Cancer	C34	114,552	72 (65-80)	45	12	123,622	72 (65-80)	44	12
	Colorectal Cancer	C18-C20	42,484	71 (61-82)	46	13	49,053	72 (62-83)	45	14
	Breast Cancer	C50	35,115	69 (59-81)	44	13	43,519	71 (61-83)	43	15
	Hematological Cancer	C81-C96	47,174	74 (67-84)	35	11	57,892	74 (67-84)	35	12
	Diabetes	E10-E14	70,763	72 (63-82)	53	17	229,326	74 (65-84)	46	19
	Alzheimer's	G30	98,675	87 (82-92)	29	50	118,993	87 (82-92)	29	48
	Ischemic Heart Disease	120-125	292,659	77 (67-88)	50	18	440,225	77 (68-87)	47	18

	Kidney Disease	N00-07, 17- 19,25-28	46,120	76 (68-87)	25	18	189,938	76 (67-87)	20	15
2020	Cancer	C00-C99	513,275	72 (64-81)	55	8	586,503	72 (64-82)	52	9
	Pancreatic Cancer	C25	39,893	72 (65-80)	61	6	42,383	72 (65-80)	60	6
	Lung Cancer	C34	115,554	72 (65-80)	54	8	127,671	72 (65-80)	53	8
	Colorectal Cancer	C18-C20	43,990	71 (61-82)	56	9	52,319	72 (62-83)	53	10
	Breast Cancer	C50	36,296	70 (60-81)	54	10	47,094	72 (62-83)	51	12
	Hematological Cancer	C81-C96	49,161	74 (67-84)	46	8	64,840	74 (68-84)	43	9
	Diabetes	E10-E14	88,124	71 (62-82)	58	15	343,061	73 (65-83)	45	16
	Alzheimer's	G30	115,256	86 (82-92)	33	46	151,206	86 (82-92)	31	47
	Ischemic Heart Disease	120-125	327,854	76 (67-88)	54	16	533,204	77 (68-87)	49	16
	Kidney Disease	N00-07, 17- 19,25-28	49,796	76 (68-87)	30	15	255,708	75 (67-86)	21	12

		Multip	le Cause	Unde	rlying Cause
Cause of death	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline
Cancer	Overall	13601*	3.0	11	0.0
	1	79	0.0	-3917*	-2.0
	2	6519*	4.0	2662	2.0
	3	7003*	6.0	1266	1.0
Pancreatic Cancer	Overall	-25	-0.0	-282	-1.0
	1	-213	-1.0	-281	-2.0
	2	44	0.0	-30	-0.0
	3	144	1.0	29	0.0
Lung Cancer	Overall	1102	1.0	-814	-1.0
	1	-729	-1.0	-1221	-3.0
	2	784	2.0	249	1.0
	3	1047	4.0	158	1.0
Breast Cancer	Overall	838	2.0	-438	-1.0
	1	-66	-0.0	-415	-3.0
	2	437	3.0	81	1.0
	3	467	5.0	-105	-1.0
Colorectal Cancer	Overall	988	2.0	-168	-0.0
	1	-169	-1.0	-463	-3.0
	2	454	3.0	112	1.0
	3	703*	6.0	183	2.0
Hematological Cancers	Overall	3615*	7.0	111	0.0
	1	546	2.0	-447	-2.0
	2	1412*	8.0	412	3.0
	3	1657*	12.0	146	1.0
Diabetes	Overall	82318*	37.0	10784*	16.0
	1	25306*	25.0	2305*	7.0
	2	27534*	38.0	4330*	20.0

Appendix 1 - Table 2. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each
 diagnosis group (National). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

	3	29477*	56.0	4148*	26.0
Alzheimer's	Overall	21712*	19.0	8528*	9.0
	1	4763*	9.0	547	1.0
	2	8054*	22.0	4257*	14.0
	3	8894*	33.0	3724*	16.0
Ischemic Heart Disease	Overall	58793*	14.0	17194*	6.0
	1	12042*	6.0	862	1.0
	2	21783*	16.0	7912*	9.0
	3	24967*	25.0	8419*	13.0
Kidney Disease	Overall	41907*	22.0	785	2.0
	1	8182*	10.0	-1048	-5.0
	2	14767*	25.0	777	5.0
	3	18958*	44.0	1056*	10.0

884 \*Confidence interval does not include zero

Appendix 1 - Table 3. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each
 diagnosis group (New York). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

		Multip	le Cause	Unde	rlying Cause
Cause of death	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline
Cancer	Overall	1012	4.0	-557	-2.0
	1	747	6.0	-474	-5.0
	2	120	1.0	-6	-0.0
	3	144	2.0	-77	-1.0
Pancreatic Cancer	Overall	-29	-1.0	-58	-3.0
	1	8	1.0	-16	-2.0
	2	-1	-0.0	-9	-1.0
	3	-37	-6.0	-33	-6.0
_ung Cancer	Overall	47	1.0	-163	-3.0
	1	27	1.0	-143	-7.0
	2	23	1.0	16	1.0
	3	-3	-0.0	-36	-3.0
Breast Cancer	Overall	205	9.0	-46	-2.0
	1	151	16.0	-34	-4.0
	2	31	4.0	3	0.0
	3	23	4.0	-15	-3.0
Colorectal Cancer	Overall	189	8.0	42	2.0
	1	91	9.0	-16	-2.0
	2	40	5.0	26	4.0
	3	58	9.0	33	6.0
Hematological Cancers	Overall	156	5.0	-149	-6.0
	1	121	10.0	-107	-11.0
	2	1	0.0	-25	-3.0
	3	35	5.0	-18	-3.0
Diabetes	Overall	7240*	66.0	866*	26.0
	1	5945*	128.0	568*	40.0
	2	631*	18.0	121	11.0

	3	664*	24.0	177	21.0
Alzheimer's	Overall	884*	26.0	233	9.0
	1	734*	49.0	188	16.0
	2	1	0.0	1	0.0
	3	150	17.0	44	6.0
Ischemic Heart Disease	Overall	7118*	25.0	3756*	17.0
	1	6607*	54.0	4092*	44.0
	2	179	2.0	-184	-3.0
	3	331	5.0	-152	-3.0
Kidney Disease	Overall	2438*	34.0	51	3.0
	1	1946*	63.0	22	3.0
	2	144	6.0	-13	-2.0
	3	349*	19.0	42	8.0

888 \*Confidence interval does not include zero

Appendix 1 - Table 4. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each
 diagnosis group (Texas). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

		Multip	le Cause	Unde	rlying Cause
Cause of death	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline
Cancer	Overall	602	2.0	-130	-0.0
	1	-48	-0.0	-62	-0.0
	2	467	4.0	39	0.0
	3	183	2.0	-107	-1.0
Pancreatic Cancer	Overall	1	0.0	5	0.0
	1	-36	-3.0	-36	-4.0
	2	17	2.0	24	3.0
	3	20	3.0	17	3.0
_ung Cancer	Overall	176	2.0	108	2.0
	1	33	1.0	31	1.0
	2	60	2.0	27	1.0
	3	84	5.0	49	3.0
Breast Cancer	Overall	-19	-1.0	-131	-5.0
	1	-54	-4.0	-54	-6.0
	2	29	3.0	-25	-3.0
	3	6	1.0	-51	-8.0
Colorectal Cancer	Overall	-12	-0.0	-92	-3.0
	1	-33	-2.0	-49	-4.0
	2	4	0.0	-34	-3.0
	3	17	2.0	-10	-1.0
Hematological Cancers	Overall	194	5.0	-12	-0.0
	1	24	2.0	1	0.0
	2	136	11.0	21	2.0
	3	33	3.0	-34	-4.0
Diabetes	Overall	8902*	49.0	618	11.0
	1	1411*	19.0	61	3.0
	2	4612*	77.0	420*	23.0

	3	2879*	62.0	138	9.0
Alzheimer's	Overall	2242*	24.0	1184	15.0
	1	309	8.0	197	6.0
	2	1398*	45.0	805*	31.0
	3	536*	21.0	181	8.0
Ischemic Heart Disease	Overall	6018*	20.0	1700	9.0
	1	736	6.0	99	1.0
	2	3376*	34.0	1228*	19.0
	3	1905*	24.0	374	7.0
Kidney Disease	Overall	6724*	47.0	579	19.0
	1	886*	15.0	115	9.0
	2	3535*	76.0	285*	28.0
	3	2303*	66.0	179	23.0

892 \*Confidence interval does not include zero

	Wave	Multiple Cause		Unde	erlying Cause
Cause of death		Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline
Cancer	Overall	991	2.0	-29	-0.0
	1	-102	-1.0	-236	-1.0
	2	564	3.0	125	1.0
	3	529	4.0	82	1.0
Pancreatic Cancer	Overall	-97	-3.0	-126	-4.0
	1	-28	-2.0	-39	-3.0
	2	-69	-5.0	-70	-6.0
	3	0	0.0	-18	-2.0
Lung Cancer	Overall	-10	-0.0	-132	-2.0
	1	-82	-3.0	-96	-3.0
	2	18	1.0	-48	-2.0
	3	54	3.0	13	1.0
Breast Cancer	Overall	67	2.0	-22	-1.0
	1	-44	-3.0	-34	-3.0
	2	92	6.0	44	4.0
	3	20	2.0	-33	-4.0
Colorectal Cancer	Overall	100	2.0	20	1.0
	1	7	0.0	-4	-0.0
	2	66	4.0	25	2.0
	3	27	2.0	-1	-0.0
Hematological Cancers	Overall	279	5.0	52	1.0
	1	0	0.0	-33	-2.0
	2	164	9.0	64	4.0
	3	114	8.0	20	2.0
Diabetes	Overall	9163*	39.0	1408*	20.0
	1	1843*	18.0	213	7.0

Appendix 1 - Table 5. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each
 diagnosis group (California). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

	2	3846*	49.0	620*	27.0
	3	3474*	59.0	575*	33.0
Alzheimer's	Overall	2143*	14.0	594	5.0
	1	375	6.0	-76	-1.0
	2	1041*	20.0	410	9.0
	3	726*	18.0	259	8.0
Ischemic Heart Disease	Overall	5905*	16.0	2888*	11.0
	1	650	4.0	104	1.0
	2	2966*	24.0	1581*	19.0
	3	2289*	25.0	1204*	19.0
Kidney Disease	Overall	3858*	21.0	8	0.0
	1	301	4.0	-114	-8.0
	2	1967*	33.0	63	6.0
	3	1590*	36.0	59	7.0

895 \*Confidence interval does not include zero

896 Appendix 1 - Figure 1. National-level weekly observed and estimated baseline mortality for each diagnosis group as both the

underlying cause or anywhere on the death certificate (multiple cause) from 2017 to 2020. Baselines during the pandemic areprojected based on the previous years of data.

.. .. .









Appendix 1 - Figure 3. Correlation between weekly number of COVID-19 coded deaths and excess multiple cause deaths for each diagnosis group (National).





New York - Underlying Cause



Appendix 1 - Figure 5. Correlation between weekly number of COVID-19 coded deaths and excess underlying deaths for each
 diagnosis group (New York).

913 Appendix 1 - Figure 6. Weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or

anywhere on the death certificate (multiple cause) from 2017 to 2020 in New York. Baselines during the pandemic are projected

915 based on the previous years of data.



#### **New York**

917 Appendix 1 - Figure 7. Weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or anywhere on the death certificate (multiple cause) from 2017 to 2020 in Texas. Baselines during the pandemic are projected based

918

919 on the previous years of data.

#### Texas



Appendix 1 - Figure 8. Weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or
 anywhere on the death certificate (multiple cause) from 2017 to 2020 in New York. Baselines during the pandemic are projected

923 based on the previous years of data.

## California



Appendix 1 - Figure 9. Comparison of ICD-10 letter categories between 2020 and 2019 for the underlying cause of death when
 cancer or diabetes are included on the death certificate, but are not listed as the underlying cause of death. For both cancer and
 diabetes, I codes (diseases of the circulatory system) make up the majority of underlying deaths. The most notable difference

- between 2019 and 2020 is the increase in U codes, which includes COVID-19 (U071). In total there were 13,434 deaths ascribed to
- 929 COVID-19 (UC deaths) among cancer MC deaths. COVID-19 was included in <3% of all cancer deaths and 17% of diabetes deaths.
- 930 In both cases it was listed as the UC on the majority of death certificates where it was included (81% and 97% for cancer and

931 diabetes, respectively).



Underlying cause when cancer or diabetes are contributing

Appendix 1 - Figure 10. Post-2020 trends in cancer, diabetes, and Alzheimer's mortality. Aggregated weekly data was downloaded from CDC
 Wonder. Trends in cancer mortality rate appear stable in the national data and in Texas and California, but decreasing in New York. The diabetes
 mortality rate is higher post-2020 compared to earlier years across all states. Alzheimer's appears stable and slowly decreasing.



937 Appendix 1 - Figure 11. For each condition three time series models with different time trends were considered (see Methods). The final model 938 for each condition and location is indicated in blue. The final model was fit to 2014-2018 data only and used to predict the 2019 data. A coverage 939 proportion (shown in white) was calculated as the proportion of observed 2019 data that fell within the projection intervals of the model. For all 940 causes of death and states (except MC Kidney disease in California) the coverage proportion was 1, indicating that all data points fell within the 941 prediction intervals.



